Zobrazeno 1 - 10
of 31
pro vyhledávání: '"ML Velloso Feijoo"'
Autor:
José M. Pego-Reigosa, E. Tomero Muriel, E. Uriarte Isacelaya, Elia Valls-Pascual, Elena Aurrecoechea, Iñigo Rúa-Figueroa, I. Jiménez-Moleón, J.A. Narváez, N. Lozano Rivas, Raúl Menor-Almagro, Eduardo Salas, Miriam Moreno, Alina Boteanu, T. R. Vazquez Rodriguez, Lorena Expósito, V. Quevedo Vila, C. A. Montilla-Morales, Antonio Fernández-Nebro, C. Mouriño, Jaime Calvo-Alén, M. Freire González, Gemma Bonilla, J.A. Bernal, Cristina Bohórquez, Tatiana Cobo-Ibáñez, Arantxa Mas, ML Velloso Feijoo, J. A. Hernandez Beriain, Roman Blanco, O. Ibarguengoitia, D. Rua-Figueroa, E. Salgado Perez, J.L. Andreu Sánchez, N. Pérez-Veiga, A. Pecondon, C. Sanguesa, María Galindo-Izquierdo, F. J. Toyos Sáenz de Miera, A. M. Anzola Alfaro, N. Del-Val
Publikováno v:
Annals of the Rheumatic Diseases. 80:610-611
Background:Factors associated with the development of chronic heart failure (CHF) in systemic lupus erythematosus (SLE) have received little attention. On the other hand, recent data from the use of hydroxychloroquine in the treatment of SARS-CoV-2 i
Autor:
I. Añón Oñate, Marta Rojas-Giménez, S. Manrique Arija, Francisco Javier Godoy-Navarrete, B. Panero Lamothe, María Isabel Padin-Martín, F. G. Jiménez-Núñez, María Carmen Aguilar-Hurtado, C.M. Romero-Barco, L. Pérez Albaladejo, Antonio Fernández-Nebro, R. Ortega Castro, R. Redondo, ML Velloso Feijoo, F. Espildora, I. Ureña, Natalia Mena-Vázquez
Publikováno v:
Annals of the Rheumatic Diseases. 80:323.1-323
Objectives:To analyze the effect of disease-modifying antirheumatic drugs (DMARDs) and identify risk factors associated with disease progression and mortality in patients with rheumatoid arthritis associated with interstitial lung disease (RA-ILD).Me
Publikováno v:
Abstracts Accepted for Publication.
Background: Efficacy and safety of the new JAK inhibitors is supported by phase I, II and III studies with a large number of patients included in the follow-up, although it is of vital importance behavior of new molecules in routine clinical practice
Publikováno v:
Annals of the Rheumatic Diseases. 79:1482.2-1482
Background:Efficacy and safety profile of new JAK inhibitors have been properly defined by several clinical trials, being tested in many patients with Arthritis Reumatoid. However, real-life conditions studies play an important role in order to know
Publikováno v:
Annals of the Rheumatic Diseases. 79:1493.2-1493
Background:Lupus nephritis (LN) is a potentially life-threatening complication of systemic lupus erythematosus (SLE). Standard treatment of this entity includes glucocorticoids (GC) and immunosuppressants such as cyclophosphamide (CF), with remission
Publikováno v:
Abstracts Accepted for Publication.
Background Systemic autoimmune diseases (SAD) have traditionally been treated with steroids and immunosuppressants, but not all patients respond to these measures. Rituximab (RTX) has been used in several SAD with favorable results, but there are onl
Publikováno v:
Abstracts Accepted for Publication.
Background Systemic autoimmune diseases (SAD) have traditionally been treated with steroids and immunosuppressants, but not all patients respond to this strategy. Rituximab (RTX) has been used in several SAD with favorable efficacy and safety results
Publikováno v:
Annals of the Rheumatic Diseases. 74:A54.1-A54
Background The frequency of stroke in SLE patients between 18–44 years is 2 times the frequency in general population of the same age and sex. Clinical atherosclerosis is detected in 6%–12% of patients with SLE. Some researchers have suggested th
Publikováno v:
Annals of the Rheumatic Diseases. 74:A53.3-A54
Background Antiphospholipid syndrome is an autoimmune disease characterised by venous and arterial relapsing thrombosis, recurrent miscarriages and thrombocytopenia. Nonarteritic anterior ischaemic optic neuropathy (AION) is a condition characterised
Publikováno v:
Annals of the Rheumatic Diseases. 73:66.1-66
Background The 2010 ACR/EULAR classification criteria for rheumatoid arthritis (RA), which include antibodies to citrullinated peptide (ACPA) have good sensitivity and specificity for diagnosing of AR in advanced stages. However, early diagnosis is a